Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (1->4)-beta-D-glucan | multiple interactions | ISO | Ube2k (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of UBE2K mRNA | CTD | PMID:36331819 | 1,2-dichloroethane | increases expression | ISO | Ube2k (Mus musculus) | 6480464 | ethylene dichloride results in increased expression of UBE2K mRNA | CTD | PMID:28960355 | 1,2-dimethylhydrazine | multiple interactions | ISO | Ube2k (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of UBE2K mRNA | CTD | PMID:22206623 | 1,2-dimethylhydrazine | decreases expression | ISO | Ube2k (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of UBE2K mRNA | CTD | PMID:22206623 | 17alpha-ethynylestradiol | multiple interactions | ISO | Ube2k (Mus musculus) | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of UBE2K mRNA | CTD | PMID:17942748 | 17alpha-ethynylestradiol | increases expression | ISO | Ube2k (Mus musculus) | 6480464 | Ethinyl Estradiol results in increased expression of UBE2K mRNA | CTD | PMID:17555576 and PMID:17942748 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | Ube2k (Mus musculus) | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of UBE2K mRNA | CTD | PMID:17942748 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Ube2k (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of UBE2K mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Ube2k (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of UBE2K mRNA | CTD | PMID:19465110 | 2,4-dinitrotoluene | affects expression | EXP | | 6480464 | 2 and 4-dinitrotoluene affects the expression of UBE2K mRNA | CTD | PMID:21346803 | 2,6-dinitrotoluene | affects expression | EXP | | 6480464 | 2 and 6-dinitrotoluene affects the expression of UBE2K mRNA | CTD | PMID:21346803 | 2-methylcholine | affects expression | ISO | UBE2K (Homo sapiens) | 6480464 | beta-methylcholine affects the expression of UBE2K mRNA | CTD | PMID:21179406 | 3H-1,2-dithiole-3-thione | increases expression | ISO | Ube2k (Mus musculus) | 6480464 | 1 and 2-dithiol-3-thione results in increased expression of UBE2K mRNA | CTD | PMID:15375163 | acetylsalicylic acid | increases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Aspirin results in increased expression of UBE2K mRNA | CTD | PMID:11906190 | aflatoxin B1 | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased expression of UBE2K mRNA | CTD | PMID:21641981 | all-trans-retinoic acid | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Tretinoin results in decreased expression of UBE2K mRNA | CTD | PMID:33167477 | aminoglutethimide | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Aminoglutethimide results in decreased expression of UBE2K protein | CTD | PMID:26102013 | aristolochic acid A | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | aristolochic acid I results in decreased expression of UBE2K mRNA | CTD | PMID:33212167 | aristolochic acid A | increases expression | ISO | UBE2K (Homo sapiens) | 6480464 | aristolochic acid I results in increased expression of UBE2K protein | CTD | PMID:33212167 | Aroclor 1254 | decreases expression | ISO | Ube2k (Mus musculus) | 6480464 | Chlorodiphenyl (54% Chlorine) results in decreased expression of UBE2K mRNA | CTD | PMID:23650126 | arsane | affects methylation | ISO | UBE2K (Homo sapiens) | 6480464 | Arsenic affects the methylation of UBE2K gene | CTD | PMID:25304211 | arsenic atom | affects methylation | ISO | UBE2K (Homo sapiens) | 6480464 | Arsenic affects the methylation of UBE2K gene | CTD | PMID:25304211 | atrazine | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Atrazine results in decreased expression of UBE2K mRNA | CTD | PMID:22378314 | benzo[a]pyrene | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased expression of UBE2K mRNA | CTD | PMID:20064835 | benzo[a]pyrene | increases expression | ISO | Ube2k (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased expression of UBE2K mRNA | CTD | PMID:22228805 and PMID:27195522 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | 7 more ... | CTD | PMID:19150397 and PMID:26238291 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of UBE2K mRNA | CTD | PMID:25181051 | bisphenol A | decreases expression | ISO | Ube2k (Mus musculus) | 6480464 | bisphenol A results in decreased expression of UBE2K protein | CTD | PMID:35999755 | bisphenol A | increases methylation | ISO | UBE2K (Homo sapiens) | 6480464 | bisphenol A results in increased methylation of UBE2K gene | CTD | PMID:31601247 | bisphenol A | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | bisphenol A results in decreased expression of UBE2K mRNA and bisphenol A results in decreased expression of UBE2K protein | CTD | PMID:29275510 and PMID:37567409 | Brodifacoum | increases expression | EXP | | 6480464 | bromfenacoum results in increased expression of UBE2K protein | CTD | PMID:28903499 | cadmium dichloride | increases expression | ISO | Ube2k (Mus musculus) | 6480464 | Cadmium Chloride results in increased expression of UBE2K mRNA | CTD | PMID:20061341 | cannabidiol | multiple interactions | ISO | UBE2K (Homo sapiens) | 6480464 | [Cuprizone co-treated with Cannabidiol] results in decreased expression of UBE2K protein | CTD | PMID:34122009 | chenodeoxycholic acid | multiple interactions | ISO | UBE2K (Homo sapiens) | 6480464 | [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA | CTD | PMID:32152650 | chlorpyrifos | increases expression | ISO | Ube2k (Mus musculus) | 6480464 | Chlorpyrifos results in increased expression of UBE2K mRNA | CTD | PMID:29156651 | cisplatin | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Cisplatin results in decreased expression of UBE2K mRNA | CTD | PMID:27594783 | clofibrate | increases expression | ISO | Ube2k (Mus musculus) | 6480464 | Clofibrate results in increased expression of UBE2K mRNA | CTD | PMID:23811191 | cobalt dichloride | increases expression | ISO | UBE2K (Homo sapiens) | 6480464 | cobaltous chloride results in increased expression of UBE2K mRNA | CTD | PMID:19320972 | copper(II) sulfate | increases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Copper Sulfate results in increased expression of UBE2K mRNA | CTD | PMID:19549813 | Cuprizon | decreases expression | EXP | | 6480464 | Cuprizone results in decreased expression of UBE2K mRNA | CTD | PMID:26577399 | Cuprizon | multiple interactions | ISO | UBE2K (Homo sapiens) | 6480464 | [Cuprizone co-treated with Cannabidiol] results in decreased expression of UBE2K protein | CTD | PMID:34122009 | cyclosporin A | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Cyclosporine results in decreased expression of UBE2K mRNA | CTD | PMID:22147139 | cyclosporin A | multiple interactions | ISO | UBE2K (Homo sapiens) | 6480464 | [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA | CTD | PMID:32152650 | deoxycholic acid | multiple interactions | ISO | UBE2K (Homo sapiens) | 6480464 | [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA | CTD | PMID:32152650 | dieldrin | increases response to substance | ISO | UBE2K (Homo sapiens) | 6480464 | UBE2K gene mutant form results in increased susceptibility to Dieldrin | CTD | PMID:32421776 | doxorubicin | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Doxorubicin results in decreased expression of UBE2K mRNA | CTD | PMID:29803840 | ethanol | affects splicing | ISO | Ube2k (Mus musculus) | 6480464 | Ethanol affects the splicing of UBE2K mRNA | CTD | PMID:30319688 | ethyl methanesulfonate | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Ethyl Methanesulfonate results in decreased expression of UBE2K mRNA | CTD | PMID:23649840 | flutamide | increases expression | EXP | | 6480464 | Flutamide results in increased expression of UBE2K mRNA | CTD | PMID:24136188 | folic acid | multiple interactions | ISO | Ube2k (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of UBE2K mRNA | CTD | PMID:22206623 | formaldehyde | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Formaldehyde results in decreased expression of UBE2K mRNA | CTD | PMID:23649840 | furan | decreases expression | EXP | | 6480464 | furan results in decreased expression of UBE2K mRNA | CTD | PMID:25539665 | glycochenodeoxycholic acid | multiple interactions | ISO | UBE2K (Homo sapiens) | 6480464 | [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA | CTD | PMID:32152650 | glycocholic acid | multiple interactions | ISO | UBE2K (Homo sapiens) | 6480464 | [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA | CTD | PMID:32152650 | glycodeoxycholic acid | multiple interactions | ISO | UBE2K (Homo sapiens) | 6480464 | [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA | CTD | PMID:32152650 | isotretinoin | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Isotretinoin results in decreased expression of UBE2K mRNA | CTD | PMID:20436886 | ivermectin | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Ivermectin results in decreased expression of UBE2K protein | CTD | PMID:32959892 | lead diacetate | affects expression | EXP | | 6480464 | lead acetate affects the expression of UBE2K protein | CTD | PMID:36539177 | lead(0) | affects splicing | ISO | UBE2K (Homo sapiens) | 6480464 | Lead affects the splicing of UBE2K mRNA | CTD | PMID:28903495 | mechlorethamine | increases expression | ISO | Ube2k (Mus musculus) | 6480464 | Mechlorethamine results in increased expression of UBE2K mRNA | CTD | PMID:17107856 | methidathion | decreases expression | ISO | Ube2k (Mus musculus) | 6480464 | methidathion results in decreased expression of UBE2K mRNA | CTD | PMID:34813904 | methyl methanesulfonate | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Methyl Methanesulfonate results in decreased expression of UBE2K mRNA | CTD | PMID:23649840 | methylmercury chloride | increases expression | ISO | Ube2k (Mus musculus) | 6480464 | methylmercuric chloride results in increased expression of UBE2K mRNA | CTD | PMID:20061341 | methylmercury chloride | increases expression | ISO | UBE2K (Homo sapiens) | 6480464 | methylmercuric chloride results in increased expression of UBE2K mRNA | CTD | PMID:28001369 | methylparaben | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | methylparaben results in decreased expression of UBE2K mRNA | CTD | PMID:31745603 | N-methyl-4-phenylpyridinium | decreases expression | ISO | Ube2k (Mus musculus) | 6480464 | 1-Methyl-4-phenylpyridinium results in decreased expression of UBE2K protein | CTD | PMID:26558463 | nefazodone | increases expression | EXP | | 6480464 | nefazodone results in increased expression of UBE2K mRNA | CTD | PMID:24136188 | nimesulide | increases expression | EXP | | 6480464 | nimesulide results in increased expression of UBE2K mRNA | CTD | PMID:24136188 | paracetamol | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Acetaminophen results in decreased expression of UBE2K mRNA | CTD | PMID:21420995 | pentachlorophenol | increases expression | ISO | Ube2k (Mus musculus) | 6480464 | Pentachlorophenol results in increased expression of UBE2K mRNA | CTD | PMID:23892564 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Ube2k (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of UBE2K mRNA | CTD | PMID:36331819 | pirinixic acid | increases expression | ISO | Ube2k (Mus musculus) | 6480464 | pirinixic acid results in increased expression of UBE2K mRNA | CTD | PMID:15375163 and PMID:23811191 | rotenone | increases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Rotenone results in increased expression of UBE2K mRNA | CTD | PMID:33512557 | SB 431542 | multiple interactions | ISO | UBE2K (Homo sapiens) | 6480464 | [LDN 193189 co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with FGF2 protein] results in decreased expression of UBE2K protein | CTD | PMID:37664457 | sodium arsenate | increases expression | ISO | Ube2k (Mus musculus) | 6480464 | sodium arsenate results in increased expression of UBE2K mRNA | CTD | PMID:21795629 | sodium arsenite | multiple interactions | ISO | UBE2K (Homo sapiens) | 6480464 | TP53 protein affects the reaction [sodium arsenite results in increased expression of UBE2K mRNA] | CTD | PMID:16966095 | sodium dichromate | increases expression | ISO | Ube2k (Mus musculus) | 6480464 | sodium bichromate results in increased expression of UBE2K mRNA | CTD | PMID:22155349 | sodium dichromate | increases expression | EXP | | 6480464 | sodium bichromate results in increased expression of UBE2K mRNA | CTD | PMID:22561333 | tamoxifen | affects expression | ISO | Ube2k (Mus musculus) | 6480464 | Tamoxifen affects the expression of UBE2K mRNA | CTD | PMID:17555576 | tert-butyl hydroperoxide | increases expression | ISO | UBE2K (Homo sapiens) | 6480464 | tert-Butylhydroperoxide results in increased expression of UBE2K mRNA | CTD | PMID:15336504 | valproic acid | affects expression | ISO | UBE2K (Homo sapiens) | 6480464 | Valproic Acid affects the expression of UBE2K mRNA | CTD | PMID:25979313 | valproic acid | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of UBE2K mRNA | CTD | PMID:23179753 and PMID:27188386 | vinclozolin | decreases methylation | EXP | | 6480464 | vinclozolin results in decreased methylation of UBE2K gene | CTD | PMID:31682807 | vorinostat | decreases expression | ISO | UBE2K (Homo sapiens) | 6480464 | vorinostat results in decreased expression of UBE2K mRNA | CTD | PMID:27188386 | |